Differential inhibition of platelet function by cilostazol in combination with clopidogrel
ConclusionsThe inhibitory effects of adjunctive cilostazol added to clopidogrel on platelet function differed by type of platelet function test. VerifyNow % inhibition and PRI were more inhibited than the other platelet function tests.Trial registrationCSPS.com substudy in TWMU (UMIN000026672), registered on April 1, 2017. This study was performed as a substudy of CSPS.com (UMIN000012180, registered on October 31, 2013) and was retrospectively registered. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - December 1, 2023 Category: Drugs & Pharmacology Source Type: research
Japanese nationwide questionnaire survey on delayed cerebral infarction due to vasospasm after subarachnoid hemorrhage
ConclusionsThis study elucidated the trends in prophylactic drugs to prevent cerebral vasospasm and frequency of DCI after aneurysmal SAH in Japan. Coil embolization and cilostazol administration showed effectiveness in reducing DCI related to cerebral vasospasm in 2021. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - November 2, 2023 Category: Neurology Source Type: research
Potentially active compounds that improve PAD through angiogenesis: A review
This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.PMID:37879211 | DOI:10.1016/j.biopha.2023.115634 (Source: Atherosclerosis)
Source: Atherosclerosis - October 25, 2023 Category: Cardiology Authors: Zi-Bo Liu Xin-Yun Fan Chen-Wei Wang Xun Ye Chun-Jie Wu Source Type: research
Potentially active compounds that improve PAD through angiogenesis: A review
This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.PMID:37879211 | DOI:10.1016/j.biopha.2023.115634 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 25, 2023 Category: Drugs & Pharmacology Authors: Zi-Bo Liu Xin-Yun Fan Chen-Wei Wang Xun Ye Chun-Jie Wu Source Type: research
Potentially active compounds that improve PAD through angiogenesis: A review
This study aims to summarize the potential active compounds, provide a variety of options for the search for drugs for the treatment of PAD, and bring light to the treatment of patients.PMID:37879211 | DOI:10.1016/j.biopha.2023.115634 (Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie)
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 25, 2023 Category: Drugs & Pharmacology Authors: Zi-Bo Liu Xin-Yun Fan Chen-Wei Wang Xun Ye Chun-Jie Wu Source Type: research
Cilostazol promotes blood vessel formation and bone regeneration in a murine non-union model
Biomed Pharmacother. 2023 Oct 19;168:115697. doi: 10.1016/j.biopha.2023.115697. Online ahead of print.ABSTRACTNon-unions represent a major complication in trauma and orthopedic surgery. Many factors contribute to bone regeneration, out of which an adequate vascularization has been recognized as crucial. The phosphodiesterase-3 (PDE-3) inhibitor cilostazol has been shown to exert pro-angiogenic and pro-osteogenic effects in a variety of preclinical studies. Hence, we herein investigated the effects of cilostazol on bone regeneration in an atrophic non-union model in mice. For this purpose, a 1.8 mm femoral segmental defect ...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - October 21, 2023 Category: Drugs & Pharmacology Authors: Maximilian M Menger Michelle Bleimehl David Bauer Claudia Scheuer Sandra Hans Dominik Saul Sabrina Ehnert Michael D Menger Tina Histing Matthias W Laschke Source Type: research
Angiotensin-converting enzyme insertion/deletion gene polymorphism and the progression of cerebral microbleeds
ConclusionThe progression of CMBs over 2 years was greater in the ACE DD carriers compared with the combined II/ID carriers. The results of our study indicate a possible association between the ACE I/D polymorphism and CMB. A study with a larger sample size is needed to confirm this association. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - October 12, 2023 Category: Neurology Source Type: research
Tailored antiplatelet therapy in stent assisted coiling for unruptured aneurysms: a nationwide registry study
Conclusion
Tailored antiplatelet therapy in stent assisted coiling for unruptured aneurysms reduced thromboembolic events and poor outcomes without increasing bleeding. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - October 12, 2023 Category: Neurosurgery Authors: Koh, J. S., Hwang, G., Park, J. C., Lee, C.-Y., Chung, J., Lee, S.-W., Kwon, H.-J., Kim, S.-R., Kang, D.-H., Kwon, S. C., Kim, S.-T., Chang, C. H., Jang, D.-K., Choi, J. H., Kim, Y. W., Kim, B.-T., Shin, B. G., You, S. H., Chung, S. Y., Ko, J., Kim, T. G. Tags: Hemorrhagic stroke Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
Cilostazol for the management of moyamoya disease: a systematic review of the early evidence, efficacy, safety, and future directions
Neurosurg Focus. 2023 Oct;55(4):E9. doi: 10.3171/2023.7.FOCUS23327.ABSTRACTSurgical revascularization remains the standard treatment for symptomatic moyamoya disease (MMD). As with any major surgical treatment, revascularization is associated with risks and limitations, denoting the need for noninvasive treatments to improve ischemic symptoms and prevent strokes. Cilostazol is a selective phosphodiesterase III inhibitor with antiplatelet, antithrombotic, and vasodilatory effects commonly used in peripheral vascular disease. Clinical studies assessing the efficacy of cilostazol in the management of stroke and MMD were recen...
Source: Neurosurgical Focus - October 1, 2023 Category: Neurosurgery Authors: Aidin Abedi Saman Sizdahkhani Wooseong Choi Vincent N Nguyen Robert C Rennert Jonathan J Russin Source Type: research
